-
Product Insights
NewCutaneous Lupus Erythematosus – Drugs In Development, 2024
Empower your strategies with our Cutaneous Lupus Erythematosus – Drugs In Development, 2024 report and make more profitable business decisions. Cutaneous lupus erythematosus (CLE) is lupus affecting the skin. It is a diverse group of autoimmune connective tissue disorders localised to the skin that can be associated with systemic lupus erythematosus (SLE) to varying degrees. Cutaneous lupus erythematosus (CLE) is classified as Acute (ACLE), Subacute (SCLE), Intermittent (lupus tumidus) and chronic (CCLE) eg, discoid lupus (DLE), lupus profundus, chilblain lupus erythematosus....
-
Product Insights
NewHematopoietic Stem Cell Transplantation – Drugs In Development, 2024
Empower your strategies with our Hematopoietic Stem Cell Transplantation – Drugs In Development, 2024 report and make more profitable business decisions. Hematopoietic stem-cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood in order to replicate inside of a patient and to produce additional normal blood cells. It may be autologous (the patient's own stem cells are used), allogeneic (the stem cells come from a donor) or syngeneic (from...
-
Product Insights
NewAnaphylaxis – Drugs In Development, 2024
Empower your strategies with our Anaphylaxis – Drugs In Development, 2024 report and make more profitable business decisions. Anaphylaxis is a severe, potentially life-threatening allergic reaction. Anaphylaxis symptoms include dizziness, nausea, vomiting or diarrhea, feeling of warmth, constriction of the airways, and a swollen tongue or throat. Risk factors include personal history of anaphylaxis, allergies or asthma, and family history. Treatment includes beta-agonists, antihistamines, and cortisone. The Anaphylaxis drugs in development market research report provide comprehensive information on the therapeutics under...
-
Product Insights
NewGranulomatosis with Polyangiitis (Wegener’s Granulomatosis) – Drugs In Development, 2024
Empower your strategies with our Granulomatosis with Polyangiitis (Wegener's Granulomatosis) – Drugs In Development, 2024 report and make more profitable business decisions. Wegener polyangiitis is an uncommon disorder that causes inflammation of blood vessels. This inflammation restricts blood flow to various organs. Signs and symptoms include constantly runny nose, nose bleeds, ear infections, cough, chest pain, skin sores, and fever. Predisposing factors include age. Treatment includes immunosuppressants and corticosteroids. The Granulomatosis with Polyangiitis (Wegener's Granulomatosis) drugs in development market research report...
-
Product Insights
NewLung Transplant Rejection – Drugs In Development, 2024
Empower your strategies with our Lung Transplant Rejection – Drugs In Development, 2024 report and make more profitable business decisions. Lung transplantation is the therapy used in various lung diseases. A lung transplant replaces an injured or diseased lung with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted lung as foreign and may work against it. Patients may hence develop complications and eventually reject...
-
Product Insights
NewChronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) – Drugs In Development, 2024
Empower your strategies with our Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) – Drugs In Development, 2024 report and make more profitable business decisions. Chronic Cutaneous Lupus Erythematosus also known as discoid lupus is a group of autoimmune disorders affecting the major areas of skin that can be associated with SLE. CLE is classified as acute, subacute, intermittent, and chronic. Although the cause is unknown major concerns are genetic, innate, and adaptive immune responses, smoking, exposure to sun,...
-
Product Insights
NewGrass Pollen Allergy – Drugs In Development, 2024
Empower your strategies with our Grass Pollen Allergy – Drugs In Development, 2024 report and make more profitable business decisions. Grass pollen allergy is a reaction which occurs soon after exposure to pollen from grasses. Signs and symptoms include skin reactions such as hives, redness, or swelling; itching or tingling in or around the mouth and throat; tightening of the throat; shortness of breath or wheezing; and runny nose. Predisposing factors include age, family history, and other allergies. The Grass Pollen...
-
Product Insights
NewDelayed Graft Function (DGF) – Drugs In Development, 2024
Empower your strategies with our Delayed Graft Function (DGF) – Drugs In Development, 2024 report and make more profitable business decisions. Delayed graft function (DGF) is an indication of acute kidney injury (AKI) occurring after a kidney transplant, with attributes unique to the transplant process. AKI is defined as an increase in serum creatinine within 48 hours of an inciting event. In the case of a transplant, the timing is less straightforward. The diagnosis of DGF is complicated by a variety...
-
Product Insights
NewCorneal Graft Rejection – Drugs In Development, 2024
Empower your strategies with our Corneal Graft Rejection – Drugs In Development, 2024 report and make more profitable business decisions. Corneal graft rejection comprises a sequence of complex immune responses that involves the recognition of the foreign histocompatibility antigens of the corneal graft by the host's immune system, leading to the initiation of the immune response cascade. An efferent immune response is mounted by the host immune system against these foreign antigens culminating in rejection and graft decompensation in irreversible cases...